These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 36562909)
1. Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Alvarez A; Bernal AM; Anampa J Breast Cancer Res Treat; 2023 Feb; 198(1):75-88. PubMed ID: 36562909 [TBL] [Abstract][Full Text] [Related]
2. Disparities in receipt of 1- Pilehvari A; Kimmick G; You W; Bonilla G; Anderson R Breast Cancer Res; 2024 Oct; 26(1):144. PubMed ID: 39425174 [TBL] [Abstract][Full Text] [Related]
3. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer. Brufsky A; Kwan ML; Sandin R; Stergiopoulos S; Karanth S; Cha-Silva AS; Makari D; Goyal RK Breast Cancer Res Treat; 2024 Nov; 208(2):223-235. PubMed ID: 39177933 [TBL] [Abstract][Full Text] [Related]
4. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy. Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405 [TBL] [Abstract][Full Text] [Related]
5. Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study. Choong GM; Liddell S; Ferre RAL; O'Sullivan CC; Ruddy KJ; Haddad TC; Hobday TJ; Peethambaram PP; Liu MC; Goetz MP; Giridhar KV Breast Cancer Res Treat; 2022 Nov; 196(1):229-237. PubMed ID: 36045271 [TBL] [Abstract][Full Text] [Related]
6. Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Futamura M; Nakayama T; Yoshinami T; Oshiro C; Ishihara M; Morita M; Watanabe A; Tanigichi A; Tsukabe M; Shimoda M; Nitta K; Chihara Y; Yasojima H; Ouchi Y; Tokumaru Y; Masuda N Breast Cancer; 2023 Nov; 30(6):943-951. PubMed ID: 37486454 [TBL] [Abstract][Full Text] [Related]
7. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors. Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421 [TBL] [Abstract][Full Text] [Related]
8. First- vs second-line CDK 4/6 inhibitor use for patients with hormone receptor positive, human epidermal growth-factor receptor-2 negative, metastatic breast cancer in the real world setting. Kimmick G; Pilehvari A; You W; Bonilla G; Anderson R Breast Cancer Res Treat; 2024 Nov; 208(2):263-273. PubMed ID: 38922546 [TBL] [Abstract][Full Text] [Related]
9. Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort. Pla H; Felip E; Obadia V; Pernas S; Viñas G; Margelí M; Fort-Culillas R; Del Barco S; Sabaté N; Fort E; Lezcano C; Cirauqui B; Quiroga V; Stradella A; Gil Gil M; Esteve A; Recalde S Clin Transl Oncol; 2024 Jul; 26(7):1748-1758. PubMed ID: 38519708 [TBL] [Abstract][Full Text] [Related]
10. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i. Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer. Jeong H; Jeong JH; Kim JE; Ahn JH; Jung KH; Kim SB Cancer Res Treat; 2022 Apr; 54(2):469-477. PubMed ID: 34176251 [TBL] [Abstract][Full Text] [Related]
12. CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial. Schettini F; Palleschi M; Mannozzi F; Brasó-Maristany F; Cecconetto L; Galván P; Mariotti M; Ferrari A; Scarpi E; Miserocchi A; Nanni O; Sanfeliu E; Prat A; Rocca A; De Giorgi U Oncologist; 2024 May; 29(5):e622-e634. PubMed ID: 38175669 [TBL] [Abstract][Full Text] [Related]
13. Overall survival and progression-free survival with cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy in breast cancer: an updated meta-analysis of randomized controlled trials. Tian Q; Gao H; Zhou Y; Yang J Eur Rev Med Pharmacol Sci; 2021 Dec; 25(23):7252-7267. PubMed ID: 34919224 [TBL] [Abstract][Full Text] [Related]
14. Social determinants of health and CDK4/6 inhibitor use and outcomes among patients with metastatic breast cancer. Sathe C; Accordino MK; DeStephano D; Shah M; Wright JD; Hershman DL Breast Cancer Res Treat; 2023 Jul; 200(1):85-92. PubMed ID: 37157005 [TBL] [Abstract][Full Text] [Related]
15. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor-Positive, ERBB2-Negative Breast Cancer: A Review. O'Sullivan CC; Clarke R; Goetz MP; Robertson J JAMA Oncol; 2023 Sep; 9(9):1273-1282. PubMed ID: 37382948 [TBL] [Abstract][Full Text] [Related]
16. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data. Martin JM; Handorf EA; Montero AJ; Goldstein LJ Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450 [TBL] [Abstract][Full Text] [Related]
17. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Goyal RK; Chen H; Abughosh SM; Holmes HM; Candrilli SD; Johnson ML Cancer; 2023 Apr; 129(7):1051-1063. PubMed ID: 36760031 [TBL] [Abstract][Full Text] [Related]
18. First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study. Basile D; Gerratana L; Corvaja C; Pelizzari G; Franceschin G; Bertoli E; Palmero L; Zara D; Alberti M; Buriolla S; Da Ros L; Bonotto M; Mansutti M; Spazzapan S; Cinausero M; Minisini AM; Fasola G; Puglisi F Breast; 2021 Jun; 57():104-112. PubMed ID: 33812267 [TBL] [Abstract][Full Text] [Related]
19. Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. Gerratana L; Davis AA; Velimirovic M; Reduzzi C; Clifton K; Bucheit L; Hensing WL; Shah AN; Pivetta T; Dai CS; D'Amico P; Wehbe F; Medford A; Wander SA; Gradishar WJ; Behdad A; Ma CX; Puglisi F; Bardia A; Cristofanilli M JCO Precis Oncol; 2023 May; 7():e2200531. PubMed ID: 37141549 [TBL] [Abstract][Full Text] [Related]
20. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer. Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]